Oct. 23 (Bloomberg) -- A Pfizer Inc. unit ignored patient safety when it sold the hormone-replacement drug Prempro without regard to the medicine’s breast-cancer risk, a lawyer said at the end of a trial in Philadelphia.

Read the original article
Brought to you by Yahoo! News

Return to Epilepsy News